EANS-Adhoc: LifeWatch announces the appointments of Dr. Andrea Natale and Dr. John F. Beshai to its Medical Advisory Board

--------------------------------------------------------------------------------
Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer
europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich.
--------------------------------------------------------------------------------

Forschung/Entwicklung/Medical Advisory Board

12.05.2009

Neuhausen am Rheinfall / Switzerland and Chicago / USA, May 12, 2009
- Card Guard AG's (SIX Swiss Exchange: CARDG) American subsidiary
LifeWatch Services, Inc., the leader in the provision of wireless
telemedicine services in the U.S., announced that Andrea Natale,
M.D., and John F. Beshai, M.D., have joined the Company's Medical
Advisory Board (MAB). The LifeWatch MAB is comprised of renowned
physicians and researchers in the fields of cardiology and
electro-physiology. In their capacity as MAB members Dr. Natale and
Dr. Beshai will provide guidance and support in the development of
LifeWatch's clinical strategy and patient care programs for Atrial
Fibrillation and Syncope.

"We are extremely pleased and excited to have such esteemed
colleagues become part of LifeWatch's Medical Advisory board", stated
Harry Kopelman, M.D., LifeWatch Medical Advisory Board Chairman. "Dr.
Beshai and Dr. Natale will accelerate our efforts and deepen our
clinical expertise", he added.

Dr. Andrea Natale is a world renowned electrophysiologist and was the
first electrophysiologist in the U.S. to perform percutaneous
epicardial radiofrequency ablation, which is a treatment for people
who fail conventional ablation. Dr. Natale has served as director of
the electrophysiology laboratory at Duke University, director of the
electrophysiology program at the University of Kentucky, Lexington,
and as a professor at prestigious universities, including Duke
University and Stanford University. In addition to serving on the
editorial boards of numerous medical journals, he is editor-in-chief
of the Journal of Atrial Fibrillation. Dr. Natale graduated summa cum
laude from the Medical School of the University of Florence, Italy,
and summa cum laude from the Catholic University School of Cardiology
in Rome, Italy. He received his clinical training in cardiology at
Methodist Hospital, Baylor College in Houston and at the University
of Western Ontario in London, Ontario, Canada. After completing a
clinical fellowship in cardiology (electrophysiology) at the
University of Western Ontario in 1991, he further trained in
cardiology (electrophysiology) at the University of Wisconsin, Sinai
Samaritan Medical Center in Milwaukee.

Dr. John Beshai serves as the Director of Pacemaker and Defibrillator
Services at the University of Chicago, and is an Assistant Professor
of Medicine at the University of Chicago's Pritzker School of
Medicine. Dr. Beshai has served as an Assistant Professor of Medicine
at the Emory University School of Medicine He completed his
fellowships in Clinical Cardiac Electrophysiology and Cardiovascular
Medicine from the Hospital of the University of Pennsylvania, and has
a fellowship in Cardiovascular Medicine from the New England Medical
Center at Tufts University School of Medicine in Boston. Dr. Beshai
completed his undergraduate degree at The Ohio State University
followed by his Medical Degree at St. George's University in 1996. He
served as National P.I. and Steering Committee Chairman for the
Resynchronization Therapy in Patients with Heart Failure and Narrow
QRS (RETHINQ). In addition, he serves as a peer reviewer for
numerous journals including JCE, HRS, and AJC.

LifeWatch Medical Advisory Board:

Harry Kopelman, M.D. - Atlanta, GA

Dr. Kopelman is Co-Director of Electrophysiology Research and
affiliate Scientist at the Piedmont Heart Institute where he has
played a central role in the program's development an in ongoing
clinical and pre-clinical research.

John F. Beshai, M.D., F.A.C.C., F.H.R.S. - Chicago, IL

Dr. John Beshai serves as the Director of Pacemaker and Defibrillator
Services at the University of Chicago, and is an Assistant Professor
of Medicine at the University of Chicago's Pritzker School of
Medicine

Alan Kadish, M.D., F.A.C.C., F.H.R.S - Evanston, IL

Dr. Kadish is a fellow of both the American College of Cardiology and
the American Heart Association, and sits on the editorial board or is
an Editorial Consultant for more than a dozen cardiology journals.
Dr. Kadish serves as Senior Associate Chief of Cardiology at
Northwestern Memorial Hospital.

Andrea Natale, M.D., F.A.C.C., F.H.R.S. - San Francisco, CA

Dr. Natale is the Senior Medical Director of the California Pacific
Medical Center for Atrial Fibrillation and Arrhythmia Program in San
Francisco, CA. In addition to serving on the editorial boards of
numerous medical journals, he is editor-in-chief of the Journal of
Atrial Fibrillation. Biography of Dr. Andrea Natale

James Reiffel, M.D. F.A.C.C., F.H.R.S - NYC, NY

Dr. Reiffel is a Professor of Clinical Medicine, Columbia University
College of Physicians and Surgeons; Attending Physician, Columbia
Presbyterian Medical Center Campus.

Steve Prater, M.D. - Atlanta, GA

Dr. Prater is a board certified cardiologist and electrophysiologist.
Dr. Prater completed his Electrophysiology fellowship at Loyola
University of Chicago, and is currently a practicing
Electrophysiologist at the Piedmont Heart Institute.

About Card Guard AG

Card Guard AG, headquartered in Neuhausen am Rheinfall, Switzerland,
is a leading healthcare technology and solution company, specializing
in advanced telehealth systems and wireless cardiac monitoring
services. Card Guard services treat high-risk and chronically ill
patients, health conscious consumers and wellness programs. Card
Guard has subsidiaries in the United States, the Netherlands, Japan,
the United Kingdom, Switzerland and Israel. Card Guard AG is the
parent company of LifeWatch Services Inc., a leading US- based
cardiac monitoring service provider, and LifeWatch Technologies Inc.,
a US-based manufacturer of telecardiology products. www.cardguard.com

About LifeWatch Corp.

LifeWatch is a wholly owned subsidiary of Card Guard AG, a leading
healthcare technology and solutions provider listed on SIX Swiss
Stock Exchange (CARDG). LifeWatch Corp., through its operating
subsidiaries LifeWatch Services, Inc. and LifeWatch Technologies,
Inc. (Instromedix) is an independent provider of ambulatory cardiac
monitoring services and a manufacturer and distributor of ambulatory
cardiac and vital signs monitoring devices in the United States. Its
current services are used by physicians primarily to monitor patients
who are suspected of having heart rhythm disorders, or cardiac
arrhythmias, and its products are used by itself and by others in
connection with providing cardiac monitoring services. For more
information, visit: www.lifewatch.com.

Upcoming Card Guard Events

18 May 2009 Analysts' and Media conference Results Q1 2009

26 May 2009 Annual Shareholder Meeting of Card Guard AG in
Zurich

This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results of
operations and financial position, business strategy and plans and
objectives for future operations, are forward- looking statements.
The words "believe," "may," "will," "estimate," "continue,"
"anticipate," "intend," "expect" and similar expressions are intended
to identify forward-looking statements. Card Guard AG has based these
forward- looking statements largely on current expectations and
projections about future events and financial trends that it believes
may affect the financial condition, results of operations, business
strategy, short term and long term business operations and
objectives, and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. In light
of these risks, uncertainties and assumptions, the forward-looking
events and circumstances described may not occur and actual results
could differ materially and adversely from those anticipated or
implied in the forward- looking statements. All forward-looking
statements are based only on data available to Card Guard AG at the
time of the issue of this press release. Card Guard AG does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF CARD
GUARD AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR
AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF CARD
GUARD AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF CARD GUARD AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S.
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM CARD GUARD AG
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.

Ende der Mitteilung euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Card Guard AG
Im Internet recherchierbar: http://www.presseportal.de

Rückfragehinweis:

Kobi Ben Efraim

Chief Financial Officer

Tel +41 52 632 00 50 | Fax +41 52 632 00 51

Email kobibe@cardguard.com

Sensus Investor and Public Relations GmbH, Zürich:

Tel +41 43 366 55 11 | Fax +41 43 366 55 12

Email cardguard@sensus.ch

Branche: Gesundheitsdienste
ISIN: CH0012815459
WKN: 1281545
Index: SPI, SPIEX
Börsen: Frankfurt / Open Market (Freiverkehr) / XETRA
SIX Swiss Exchange / Hauptsegment
Berlin / Freiverkehr